Aravax Phase 2 data show PVX108 met primary endpoint in peanut allergy

The Melbourne and Oxford biotech reported statistically significant gains in peanut tolerance in children aged 4 to 11, with effects maintained six months after stopping

Aravax Phase 2 data show PVX108 met primary endpoint in peanut allergy

Aravax has reported positive topline results from its Phase 2 trial of PVX108, a peptide-based immunotherapy for peanut allergy in children, saying the study met its primary efficacy endpoint and demonstrated a favourable safety profile across a 12-month treatment course.

The trial, conducted at 14 sites across the United States and Australia, enrolled 71 children aged 4 to 11 years in its primary cohort. Participants received either 5 nmol or 50 nmol of PVX108 by monthly intradermal injection, or placebo, over 12 months. Efficacy was assessed using a double-blind, placebo-controlled food challenge following PRACTALL guidelines. A separate 24-participant pilot cohort of adolescents aged 12 to 17 years was run in parallel to assess safety.

Trial results

At the 50 nmol dose, participants showed a 2.4-fold increase in maximum tolerated dose of peanut protein from baseline, compared with a 1.2-fold change in the placebo group, a difference that was statistically significant in the intent-to-treat analysis. The company also reported that 39.4% of children in the active arm tolerated a cumulative dose of at least 443 mg of peanut protein at month 12, against 16.7% in the placebo group. For context, a single peanut contains approximately 250 to 300 mg of peanut protein.

Notably, two thirds of food challenge reactions to the baseline reactive dose in the PVX108 group were graded zero or mild at month 12, compared with 35% in the placebo group. The company reported no treatment-related anaphylaxis or serious adverse events at either dose level, and only six participants across all arms experienced any treatment-related adverse event, the most common being local administration site reactions.

A further food challenge at month 18, conducted after a six-month treatment-free period, showed maintenance or improvement of clinical effects compared with month 12. Aravax describes this as evidence of disease-modifying potential. Of the 68 participants who completed the treatment period, 87% elected to continue into a 12-month open-label extension, with results expected in the second half of 2027.

Brian Vickery, Chief of Allergy and Immunology at Children's Healthcare of Atlanta and professor at Emory University School of Medicine, who will present the full data at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix on 14 November, said the study provided "compelling early evidence that PVX108 could deliver clinically meaningful impact in peanut allergy" and that, if confirmed in larger studies, it "would represent a significant leap forward for the food allergy field."

Market context

Peanut allergy affects an estimated 1 to 2% of children in Western countries and is the leading cause of food-allergy-related anaphylaxis. The only FDA-approved oral immunotherapy for peanut allergy in children, Palforzia from Stallergenes Greer, requires daily dosing and carries a risk of treatment-induced allergic reactions, limiting uptake. A monthly intradermal peptide therapy with a clean safety readout would address both shortcomings if Phase 3 data replicate the current findings.

PVX108 holds FDA Fast Track designation, which provides more frequent agency interactions and eligibility for rolling review. Aravax has backing from Novartis Venture Fund among a syndicate of international and Australian investors, giving it credibility with larger partners who could support late-stage development. The company has not yet disclosed a Phase 3 timeline or commercial partnering strategy. How Aravax navigates the step up in trial scale and cost will be the central question for investors watching the open-label extension readout next year.